Retatrutide: A game-changer for obesity) The FDA has been increasingly vocal about its concerns regarding these unapproved products. […]
Research & Clinical Trials
New dual-action drug produces 13% weight loss in people with type 2 diabetes
People with obesity or overweight and type 2 diabetes lost up to 13.1% of their body weight with […]
Research & Clinical Trials
For People With Diabetes, GLP-1 Drugs May Be Linked to Lower Odds of a Leading Cause of Blindness
As millions of Americans have started taking GLP-1 drugs like Ozempic, Wegovy and Mounjaro to control their blood […]
Compounding & Peptide Industry
Greenwich Rx Recalls Injectable Glutathione Nationwide Over Bacterial Toxin Risk
A compounding pharmacy has issued a nationwide recall of injectable glutathione after testing raised concerns that some of […]
Research & Clinical Trials
New Class Of Weight-Loss Drugs May Have Fewer Side Effects Than GLP-1s
Experimental Weight-Loss Drug Petrelintide Shows Promise With Fewer Stomach Side Effects A new type of obesity medication could […]
Regulation & Policy
FDA Broadens Offensive Against Online Peptide Vendors, Hitting NuScience Peptides Over Pipeline Weight-Loss Injections
WASHINGTON — In its third coordinated warning on the same day, the U.S. Food and Drug Administration has […]
Regulation & Policy
FDA Fires Another Warning Shot at Online Peptide Sellers, Targeting Royal Peptides Over Unapproved Weight-Loss and Incretin Drugs
WASHINGTON — In an expanding federal sweep against the direct-to-consumer peptide market, the U.S. Food and Drug Administration […]
Regulation & Policy
FDA Targets Another Online Peptide Seller Over Illegal Weight-Loss Injections and ‘Research Only’ Claims
U.S. Food and Drug Administration flagged online seller Felicia Romero, operator of texpeptide.com, over the unlawful distribution of several high-profile injectable drugs.